Financials Giant Biogene Holding Co., Ltd.

Equities

2367

KYG3887G1091

Personal Products

Market Closed - Hong Kong S.E. Other stock markets 04:08:27 2024-07-12 am EDT			5-day change	1st Jan Change
41.6 ^HKD	-0.72%		-2.69%	+16.85%

Jul. 04	Giant Biogene Launches New Brand Vpro Featuring Vlock 4D Recombinant Collagen for Cellular Anti-Aging	CI
Jun. 13	Giant Biogene Holding Co., Ltd. Approves Payment of Special Dividend, Payable on July 5, 2024	CI

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	28,963	31,581	39,310	-	-
Enterprise Value (EV) ²	27,686	29,210	35,238	33,753	31,941
P/E ratio	30 x	22.2 x	21.4 x	16.8 x	13.7 x
Yield	-	1.34%	1.37%	1.75%	2.13%
Capitalization / Revenue	12.2 x	8.96 x	8.2 x	6.37 x	5.12 x
EV / Revenue	11.7 x	8.29 x	7.35 x	5.47 x	4.16 x
EV / EBITDA	23.8 x	17.8 x	16.5 x	12.6 x	9.77 x
EV / FCF	35.5 x	20.6 x	24.3 x	16.6 x	12.9 x
FCF Yield	2.81%	4.87%	4.11%	6.03%	7.74%
Price to Book	10.7 x	7.38 x	7.14 x	5.54 x	4.4 x
Nbr of stocks (in thousands)	976,000	976,000	1,009,220	-	-
Reference price ³	33.60	35.60	41.90	41.90	41.90
Announcement Date	3/27/23	3/25/24	-	-	-

¹HKD in Million²CNY in Million³HKD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	2,364	3,524	4,796	6,167	7,685
EBITDA ¹	1,161	1,645	2,137	2,680	3,271
EBIT ¹	1,134	1,611	2,086	2,684	3,340
Operating Margin	47.95%	45.71%	43.48%	43.52%	43.46%
Earnings before Tax (EBT) ¹	1,178	1,745	2,170	2,772	3,419
Net income ¹	1,002	1,452	1,834	2,331	2,864
Net margin	42.38%	41.19%	38.23%	37.8%	37.27%
EPS ²	1.120	1.605	1.954	2.488	3.061
Free Cash Flow ¹	779	1,421	1,450	2,035	2,473
FCF margin	32.95%	40.33%	30.23%	33%	32.18%
FCF Conversion (EBITDA)	67.1%	86.38%	67.84%	75.92%	75.61%
FCF Conversion (Net income)	77.74%	97.89%	79.08%	87.3%	86.34%
Dividend per Share ²	-	0.4772	0.5742	0.7315	0.8942
Announcement Date	3/27/23	3/25/24	-	-	-

¹CNY in Million²HKD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2
Net sales ¹	1,641	1,606	1,918	2,265	2,612
EBITDA	-	-	-	-	-
EBIT ¹	771.9	714.3	896.7	952.2	1,121
Operating Margin	47.03%	44.49%	46.74%	42.03%	42.92%
Earnings before Tax (EBT) ¹	-	-	969.5	1,026	1,250
Net income ¹	-	-	784.8	869	1,025
Net margin	-	-	40.91%	38.36%	39.25%
EPS	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	3/27/23	8/28/23	3/25/24	-	-

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	1,276	2,371	4,072	5,557	7,369
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ¹	779	1,421	1,450	2,035	2,473
ROE (net income / shareholders' equity)	54.9%	40.8%	34.4%	33.2%	32%
ROA (Net income/ Total Assets)	19.2%	36.2%	31.1%	30.3%	29.3%
Assets ¹	5,225	4,009	5,904	7,691	9,761
Book Value Per Share ²	3.150	4.820	5.870	7.560	9.520
Cash Flow per Share ²	1.030	1.810	2.310	3.040	4.030
Capex ¹	153	226	188	165	178
Capex / Sales	6.46%	6.42%	3.92%	2.68%	2.32%
Announcement Date	3/27/23	3/25/24	-	-	-

¹CNY in Million²HKD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Giant Biogene Holding Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.9 HKD

Average target price

56.58 HKD

Spread / Average Target

+35.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Personal Products

	1st Jan change	Capi.
GIANT BIOGENE HOLDING CO., LTD.	+16.71%	5.42B
PROCTER & GAMBLE COMPANY	+12.97%	391B
UNILEVER PLC	+16.20%	142B
COLGATE-PALMOLIVE COMPANY	+22.64%	80.21B
HINDUSTAN UNILEVER LIMITED	-1.12%	73.45B
ESTEE LAUDER	-30.52%	36.43B
KENVUE INC.	-16.77%	34.31B
BEIERSDORF	+1.07%	33.49B
ESSITY AB	+11.24%	18.72B
GODREJ CONSUMER PRODUCTS LIMITED	+27.25%	17.65B

Other Personal Products